Adarza to commercialize diagnostic assays in 2019

Adarza, a Serra Capital II portfolio company, is set to start selling its diagnostic assays next year. Adarza BioSystems, Inc. is a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.

Adarza said its first products will be assays for detecting inflammation, cardiovascular disease and cancer. It expects the first customers to be university researchers and drug-development companies.

Source: http://www.stltoday.com/business/columns/david-nicklaus/adarza-to-commercialize-diagnostic-assays-in/article_cbdabfc8-98cc-5284-977f-fbc19b455fcc.html